Lifecore Biomedical Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

4.20$ -2.1% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Income Statement

Lifecore Biomedical Inc. (LFCR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 34 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement LFCR
Line item	Q2 16	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q1 26	Q2 26	LTM
Revenue	135	132	136	137	127	123	136	149	141	125	125	156	153	139	143	153	156	136	131	45	140	129	43	37	48	48	39	22	27	25	30	26	38	25	33	35	36	31	23	34	125
Cost of Revenue	113	111	117	113	108	104	121	129	116	108	108	134	127	123	127	133	132	119	110	30	115	111	29	25	36	36	32	16	18	22	20	17	21	19	21	25	22	23	19	22	87
Gross Profit	23	21	19	23	20	19	16	20	25	16	17	21	26	15	16	20	24	16	21	14	25	18	15	13	11	11	7.1	5.7	8.5	2.7	10.0	8.4	17	5.4	11	9.8	14	7.8	4.5	12	38
Research & Development	1.8	1.9	2.0	2.0	3.6	2.7	3.4	3.1	3.6	2.8	2.5	2.7	3.5	2.8	2.8	2.7	2.7	2.5	2.6	1.8	2.6	2.8	1.9	2.0	2.1	2.1	2.1	2.2	2.2	2.1	2.1	2.6	2.2	2.2	1.9	2.0	2.1	2.0	1.2	1.5	6.8
Selling, General & Administrative	–	–	–	–	–	–	–	–	12	–	–	–	19	–	–	–	16	–	–	–	16	16	14	9.7	19	11	11	15	11	9.2	9.3	12	12	14	11	10	9.0	8.9	7.9	8.0	34
Total Operating Expenses	16	16	16	17	17	17	16	17	17	17	16	19	24	20	22	35	37	20	22	12	24	19	11	21	21	21	45	11	15	33	32	9.6	15	17	13	19	8.7	11	9.1	9.5	38
Operating Income	7.1	5.5	3.3	4.3	2.4	2.5	-0.6	3.2	8.1	-0.4	-0.6	2.6	2.5	-4.4	-6.0	-15	-13	-4.1	-1.5	2.4	1.2	-1.2	4.1	-8.6	-39	-9.7	-5.8	-5.4	-6.5	-8.6	-1.5	-1.2	2.1	-12	-2.0	-9.0	5.3	-3.1	-4.7	2.6	0.2
Interest Expense	0.6	0.7	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.8	0.7	1.8	2.0	2.1	2.2	2.2	3.1	3.1	3.0	2.9	5.0	7.9	3.1	4.1	3.5	3.5	4.2	3.6	4.8	3.9	4.1	3.9	5.8	5.4	5.5	5.5	5.5	6.4	7.3	7.8	27
Pre-Tax Income	7.1	5.2	2.1	5.1	2.7	3.5	0.7	3.2	8.7	0.3	-0.3	1.3	1.0	-6.1	-7.9	-17	-20	-15	-16	-1.5	-3.4	-12	1.1	-6.7	-37	-37	-12	-9.2	-11	-13	14	-29	-7.1	-16	-6.5	-15	-1.1	-9.7	-15	-6.1	-32
Income Tax Expense	2.3	1.9	0.7	1.6	0.2	1.3	0.2	-13	2.0	0.1	0.3	0.2	0.6	-1.4	-1.2	-5.3	-5.3	-4.3	-2.7	-0.1	-0.6	-2.1	-3.1	-0.1	-0.8	-0.8	0.0	0.0	0.1	–	–	0.2	-0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.4
Net Income	4.7	3.3	1.3	3.5	2.5	2.1	0.5	16	6.1	0.2	-0.6	1.1	-0.3	-4.8	-6.7	-12	-15	-11	-13	-5.5	-2.9	-9.5	-38	-13	-37	-37	-12	-13	-37	-11	14	-36	-7.1	-16	-6.6	-15	-1.1	-10.0	-15	-6.2	-32
EBITDA	10	8.4	5.8	9.1	5.7	6.8	2.3	6.6	13	4.2	3.3	7.7	9.1	0.4	-1.2	-9.8	-12	-7.1	-8.2	6.4	6.6	1.4	10	0.9	-31	-31	-6.0	-2.6	-3.2	–	–	-22	0.9	-8.9	1.0	-7.2	6.3	-7.1	-5.3	4.1	-2.0

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings